Pharma Focus Asia

Heptares Therapeutics and Kymab Limited to Develop Novel Antibody Therapeutics

Heptares Therapeutics (also known as Heptares) and Kymab Limited have entered into a strategic collaboration to discover, develop and commercialise novel antibody therapeutics.

New therapeutics will target a number of G protein-coupled receptors (GCPRs) with an initial focus on immune-oncology (a new area in the treatment of cancer).

GPCRs are generally expressed on cells of the innate and adaptive immune system. They play a major role in modulating cell migration & recruitment to the tumour environment, activation, survival, production and delineation. They can be targeted by novel immunotherapy antibodies.

To create secure antigens based on various GPCR targets, Heptares will apply its StaR® platform. Kymab will then utilise its Kymouse™ human antibody discovery platform to produce antibodies in response to immunisation with these antigens.

On the other hand, the Kymouse platform provides the possibility of finding the best-in-class antibodies with superior drug properties.

Promising leads will be progressed using the partners' corresponding skills, resources and development capabilities to bring pioneering products into the clinic.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024